ArticleJournal of translational medicine2025
Spatial transcriptomics study of Castleman disease.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical Strategies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCastleman Disease (CD) is a rare lymphoproliferative disorder of uncertain etiology, primarily characterized by painless lymphadenopathy. To further understand the possible pathogenesis of the disease, we utilized spatial transcriptomics to explore CD.
methodsSpatial transcriptomics was performed on FFPE samples from lymph nodes of three CD patients with different histologic types and one normal lymph node.
resultsThe sample was categorized by analysis into 14 clusters, including B cells, plasma cells, BECs, LECs, CD4 + T cells, CD8 + T cells, macrophages, monocytes, cycling cells, myofibroblasts, mDCs, NKCs, Tfh and NESCs. Our study showed that the lesion cells of CD might be B cells. In addition to this, we found that mesenchymal cells, especially myofibroblasts, play an important role in disease progression and there was a large heterogeneity of cellular communication between cell clusters in different histologic types of CD.
conclusionsThrough this study we have gained a better understanding of the pathogenesis of CD. It provides new ideas for the subsequent exploration of CD and directions for the development of new clinical drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.